MIAMI--(BUSINESS WIRE)--Biorasi, a leading global full-service contract research organization (CRO), has announced the start of the company’s third COVID-19 clinical trial for 2020. Taking place across the United States and Europe, the goal of the study is to evaluate the efficacy and safety of the candidate drug as an antiviral agent in hospitalized patients diagnosed with COVID-19 infections.
“We are proud to have been selected as the CRO partner to run this study,” said Chris O’Brien, CEO of Biorasi. “Sponsors with COVID-19 assets need options in terms of venue and site strategy because the epicenter is moving all the time. They also need a CRO partner that is flexible enough to stay out ahead of the virus and fast enough to strike when the iron is hot. Biorasi is a global CRO with access to patients in coronavirus hot zones. We are also extremely agile, which is essential when running studies in this patient population.”
Smart Strategies for COVID-19 Studies
The upcoming study will focus on the effect and virulence of SARS-CoV-2 and explore the prevention of potential superinfections in the lungs. Approximately 100 patients will be recruited to take part, with results in hand by Q2 2021.
This is Biorasi’s third COVID-19 trial for 2020. The first focused on the treatment of lung injuries caused by COVID-19. The second study targeted the efficacy of a prophylactic medication for maintaining the health and safety of healthcare personnel treating patients with the coronavirus.
“COVID-19 is a significant and growing health threat, prompting quick responses to develop treatments to combat the virus,” said O’Brien. “And, Biorasi is ready for action. We are proud to bring our unique solutions and dedicated teams to these urgent clinical trials.”
About Biorasi
Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.
Established in 2002, Biorasi is headquartered in Aventura, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC.
To learn more about Biorasi’s mission and vision, contact us at info@biorasi.com / (786) 388-0700.